☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
UroGen
UroGen Reports the US FDA’s NDA Acceptance of Mitomycin (UGN-102) for Treating Non-Muscle Invasive Bladder Cancer
October 16, 2024
UroGen Reports the First Patient Dosing with UGN-103 in P-III (UTOPIA) Study to Treat Low-Grade Intermediate-Risk Non-Muscle Invas...
October 3, 2024
UroGen Initiates P-III (ENVISION) Study of UGN-102 for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Ca...
February 4, 2022
Insights+: The US FDA New Drug Approvals in March and April 2020
May 15, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.